Loading...
XNAS
KIDS
Market cap519mUSD
Jul 09, Last price  
20.23USD
1D
2.38%
1Q
26.68%
IPO
7.89%
Name

OrthoPediatrics Corp

Chart & Performance

D1W1MN
XNAS:KIDS chart
P/E
—
P/S
2.20
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.37%
Rev. gr., 5y
27.16%
Revenues
236m
+15.45%
23,684,00031,004,00037,298,00045,620,00057,559,00072,552,00071,078,00098,049,000122,289,000148,732,000204,727,000236,348,000
Net income
-40m
L+4.83%
-9,549,000-7,891,000-6,572,000-8,932,000-12,025,000-13,731,000-32,944,000-16,260,0001,258,000-20,974,000-37,822,000-39,648,000
CFO
-5m
L-82.07%
-9,922,000-892,000-1,119,000-7,217,000-15,583,000-17,769,000-18,530,000-13,063,000-21,766,000-27,046,000-27,048,000-4,851,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
URL
https://www.orthopediatrics.com/
IPO date
Oct 12, 2017
Employees
203
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT